Superworth20/20 Biolabs EPS AIDX
Diluted earnings per share by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.26
20/20 Biolabs' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.26.
Earnings per share over time
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$0.26 | n/a | |
| Q1 FY26 | −$0.28 | n/a | |
| Q2 FY25 | −$0.17 | n/a | |
| Q1 FY25 | −$0.16 | n/a |
Against its peers
Companies in Industrials nearest 20/20 Biolabs' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AIDX20/20 Biolabs | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| MDRRMedalist Diversified | $3.84 | |
| BCGBinah Capital | $0.16 | |
| VIPVulcan Infrastructure & Power | $0.07 | |
| MXCMexco Energy | $0.75 | −5% a year |
| CKXCKX Lands | $1.42 | +647% a year |
| MSGMMotorsport Games | $0.43 | +187% a year |
| ATCHAtlasClear | $0.01 | |
| Peer median | $0.20 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on 20/20 Biolabs
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.